ELV

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

High

293.3099

Open

290.310

VWAP

281.41

Vol

8.39M

Mkt Cap

62.39B

Low

276.4139

Amount

2.36B

EV/EBITDA(TTM)

8.18

Total Shares

232.42M

84.15B

EV/OCF(TTM)

13.04

P/S(TTM)

0.34

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

52.36B

+7.36%

12.469

+4.17%

49.32B

+9.62%

4.598

+19.74%

48.99B

+9.54%

8.032

-4.04%

Estimates Revision

The market is revising Upward the revenue expectations for Elevance Health, Inc. (ELV) for FY2025, with the revenue forecasts being adjusted by 1.89% over the past three months. During the same period, the stock price has changed by -31.87%.

Revenue Estimates for FY2025

Revise Upward

+1.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.84%

In Past 3 Month

Stock Price

Go Down

-31.87%

In Past 3 Month

16 Analyst Rating

79.72% Upside

Wall Street analysts forecast ELV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELV is 498.00 USD with a low forecast of 428.00 USD and a high forecast of 585.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

3 Hold

0 Sell

Strong Buy

79.72% Upside

Current: 277.090

Low

428.00

Averages

498.00

High

585.00

79.72% Upside

Current: 277.090

Low

428.00

Averages

498.00

High

585.00

Barclays

Overweight

downgrade

$434 -> $358

2025-07-18

New

Reason

Barclays

Price Target

$434 -> $358

2025-07-18

New

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Elevance Health to $358 from $434 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q2 report.

Morgan Stanley

Equal Weight

downgrade

$428 -> $316

2025-07-18

New

Reason

Morgan Stanley

Price Target

$428 -> $316

2025-07-18

New

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Elevance Health to $316 from $428 and keeps an Equal Weight rating on the shares. While reduced 2025 guidance was expected, the lack of clarity into 2026 is "concerning" in light of Medicaid and exchange trend headwinds that "could prove more enduring," the analyst tells investors in a post-earnings note.

UBS

AJ Rice

Buy

maintain

$484 -> $435

2025-07-18

New

Reason

UBS

AJ Rice

Price Target

$484 -> $435

2025-07-18

New

maintain

Buy

Reason

UBS analyst AJ Rice lowered the firm's price target on Elevance Health to $435 from $484 and keeps a Buy rating on the shares following the Q2 earnings report. While it was not surprising that Elevance faced pressure in Medicaid and the Marketplace given MCO peer preannouncements, the size of the EPS reduction was greater than anticipated, the analyst tells investors in a research note. UBS believes the company can lean on its commercial and Carelon segments for earnings stability and growth during this period of volatility.

Guggenheim

Buy

downgrade

$447 -> $360

2025-07-18

New

Reason

Guggenheim

Price Target

$447 -> $360

2025-07-18

New

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Elevance Health to $360 from $447 and keeps a Buy rating on the shares. Elevance lowered 2025 EPS guidance to about $30, which "on the surface was within the realm of possibilities for resetting the 2025 earnings bar," but the analyst suspects investor questions will focus on the "true" 2025 earnings floor for the company within the current uncertain cost trend environment. However, the firm is "reluctant to throw in the towel" as greater clarity around the the second half of 2025 and 2026 set up plays out and the company executes against this new low bar, the analyst added.

Leerink

Outperform -> Market Perform

downgrade

$510 -> $310

2025-07-17

New

Reason

Leerink

Price Target

$510 -> $310

2025-07-17

New

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Elevance Health to Market Perform from Outperform with a price target of $310, down from $510, seeing limited upside in the stock. The firm downgraded Elevance citing its belief that the company will have "no apparent earnings growth" in 2026, "no meaningful investment case for improving sentiment and sector valuations," and "lingering, potential, and accelerating risks across almost all lines of business and products." Leerink added that the downgrade to Market Perform aligns with its more cautious sector view on Healthcare Providers and Managed Care.

Truist

Buy

downgrade

$500 -> $440

2025-07-16

New

Reason

Truist

Price Target

$500 -> $440

2025-07-16

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Elevance Health to $440 from $500 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm's coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Elevance Health Inc (ELV.N) is 8.29, compared to its 5-year average forward P/E of 13.92. For a more detailed relative valuation and DCF analysis to assess Elevance Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

13.92

Current PE

8.29

Overvalued PE

15.54

Undervalued PE

12.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

10.42

Current EV/EBITDA

7.04

Overvalued EV/EBITDA

11.35

Undervalued EV/EBITDA

9.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

0.64

Current PS

0.31

Overvalued PS

0.73

Undervalued PS

0.55